Search

everythinglearnresearchcommunity

for

Search:↓

A 20-year-old male experienced early hair thinning due to male pattern baldness and successfully thickened his hair using oral finasteride and topical minoxidil. The conversation highlights the importance of early action and overcoming fear of medication side effects.

Combining PRP with topical minoxidil 5% and finasteride 0.25% for hair loss treatment. One user reported success using minoxidil and finasteride with micro-needling, but not PRP.

Hair loss discussion involves PRP (platelet rich plasma) treatment. PRP doesn't stop hair loss, only promotes regrowth; minoxidil is suggested as a better alternative.

A user was prescribed betamethasone dipropionate spray for a receding hairline, which caused skin peeling and depigmentation. They stopped using it and are considering alternatives like BPC-157/TB-500 for healing.

ET-02 is seen as promising for addressing hair loss and graying, but PP405 is more advanced in development and has better publicity. Some users plan to use both treatments alongside minoxidil and dutasteride.

GT20029 and CosmeRNA are both potential hair loss treatments; GT20029 breaks down the androgen receptor, while CosmeRNA prevents its production. Continuous use is needed, but less frequently than current treatments like Minoxidil and Finasteride.

Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.

PP405 shows promise in hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil, with significant results in just four weeks. The treatment is still in early stages, with further trials needed to determine its long-term effectiveness and optimal dosage.

The conversation is about using pyrilutamide and RU58841 as topical solutions to prevent hair loss. Pyrilutamide is considered safer but less potent than RU58841, which some users find effective despite potential side effects like heart palpitations.

Men with early male pattern baldness (MPB) may have hormonal abnormalities similar to those in women with PCOS. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

Treatments for hair loss, specifically the use of minoxidil, finasteride and RU58841. Replies to this post suggest that users should share relevant information publicly rather than through direct messages.

People are waiting for KX-826 (Pyrilutamide) Phase 2 data to decide on hair loss treatments, with some considering finasteride or minoxidil in the meantime. Pyrilutamide is seen as a potentially stronger and safer alternative to finasteride, but concerns about side effects and availability remain.

PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.

The user is treating hair loss with dermarolling, a laser helmet, scalp massages, and Nizoral. They stopped using minoxidil and finasteride and are considering pumpkin seed oil and sulforaphane.

Hair loss discussion includes PRP and exosomes treatments. Questioning effectiveness and ideal candidate for these treatments.

2-Deoxy-D-Ribose is discussed as a potential hair loss treatment, but skepticism exists due to lack of human testing. The original poster uses a combination of topical Minoxidil, oral Finasteride, topical RU58841, and other treatments, reporting some hair regrowth but not significant results.

Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.

Considering a hair transplant, using Pyrilutamide, the potential availability of CosmeRNA, and the significance of taking Minoxidil and Finasteride for long-term results.

Verteporfin treatment shows promise for hair regeneration and reducing scar tissue in hair transplants. Some users plan to try verteporfin with hair transplants, and it may also be combined with PRP in future experiments.

A 21-year-old male diagnosed with telogen effluvium and male pattern baldness started taking finasteride, which initially slowed hair shedding and slightly thickened hair. The doctor recommended iron and vitamin D supplements, and the user is considering minoxidil but wants to stabilize shedding first.

An increase in libido associated with the use of Pyri, and a discussion about how it may be working comparably to other hair loss treatments such as RU58841, Finasteride and Minoxidil.

The conversation is about using Verteporfin with microneedling as a potential hair loss treatment that may regenerate hair follicles with minimal scarring. There are concerns about the optimal dosage and the DHT sensitivity of the new follicles.

The conversation is about finding a legitimate source for RU58841 in Germany, with suggestions including Receptorchem and GeneTherica. Anageninc and Chemyo do not deliver to Germany.

The conversation discusses hair loss treatments, focusing on Tsuji's hair cloning and Shiseido's RCH-01, with skepticism about their effectiveness on humans. It compares these to PRP, noting PRP's higher efficacy in studies.

GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.

A new hair loss treatment called TDM-105795 is discussed as a potential replacement or add-on to Minoxidil. Users express hope for new effective treatments.

PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.

The potential of lowering prolactin levels to regrow hair, with a reference to Bayer's drug HMI 115 which has been indicated as having this effect. Treatments mentioned include Minoxidil and Finasteride, as well as RU58841.

Mixing RU58841 with cetosomal minoxidil is discussed due to scalp irritation from ethanol PG vehicles. A mixture of the two turned bright pink when left to dry.

A 57-year-old man with male pattern hair loss and insulin resistance experienced hair regrowth and weight loss after using tirzepatide, without other hair treatments. Dysregulated glucose metabolism is linked to hair loss, with tirzepatide potentially improving hair density by normalizing insulin resistance.